Enviomycin

Summary

Enviomycin is a cyclic peptide antibiotic of the tuberactinomycin family, approved for prescription use and administered by intramuscular or intravenous injection. Historically it has been employed against mycobacterial infections such as Mycobacterium avium complex (MAC) and pulmonary tuberculosis, often in combination with rifampicin and isoniazid. Recent computational work has also explored its potential as a SARS‑CoV‑2 main protease inhibitor.

Mechanism of Action

Inhibits bacterial protein synthesis by binding to the 16S rRNA of the 30S ribosomal subunit, interfering with translocation and decoding; also disrupts cell membrane integrity in mycobacteria.

What the Research Shows

In vitro studies demonstrated that enviomycin exhibits bactericidal activity against Mycobacterium avium‑intracellulare complex, comparable to streptomycin and superior to rifampicin or ethambutol in certain strains. A clinical trial of 83 patients with cavitary MAC lung disease found that regimens containing rifampin, isoniazid and enviomycin achieved sputum‑conversion rates superior to a rifampin‑isoniazid‑ethambutol regimen, with no significant difference from a streptomycin‑based regimen. Observational studies of tuberculosis patients reported vestibular dysfunction detectable within a month of daily injections, but early testing allowed prompt discontinuation and full recovery. A 2022 in silico screening suggested enviomycin may bind the SARS‑CoV‑2 main protease, though no experimental antiviral data were presented.

Reported Benefits

Enviomycin has shown bactericidal activity against MAC organisms in laboratory assays and contributed to improved sputum conversion when added to standard antitubercular therapy, indicating therapeutic benefit in mycobacterial lung disease. Early clinical reports also describe successful use in pulmonary tuberculosis. Computational modeling points to a possible antiviral scaffold for future drug design.

Limitations of the Evidence

Evidence is limited to older, relatively small clinical studies and laboratory investigations; no recent large‑scale trials have confirmed efficacy or optimal dosing. The vestibular toxicity data highlight a safety concern that may restrict prolonged use. The SARS‑CoV‑2 protease inhibition finding is purely computational and lacks experimental validation, so its clinical relevance remains uncertain.

Safety Considerations

Repeated intramuscular or intravenous injections of enviomycin have been associated with vestibular dysfunction, typically emerging within the first month of therapy. Regular equilibrium testing (head‑shaking, Romberg, stepping tests) can detect early signs, allowing drug discontinuation and usually resulting in full recovery. No other specific adverse effects are described in the cited abstracts, but clinicians should monitor for ototoxicity and adjust treatment accordingly.

How It Is Administered

Enviomycin is supplied as a sulfate salt and administered by intramuscular or intravenous injection. Dosing regimens have historically involved daily injections in combination with other antitubercular agents, but specific protocols are not detailed in the available literature.

Routes of Administration

Goals & Uses

• Treatment of multidrug-resistant tuberculosis (MDR-TB)Infectious DiseaseModerate
• Treatment of drug-susceptible tuberculosisAntimicrobial / AntitubercularLow

Contraindications

• Pre-existing hearing loss or vestibular dysfunctionAuditory/VestibularModerate
• Hypersensitivity to enviomycin or tuberactinomycinsAllergicHigh
• Severe renal impairmentOrganHighKidney function concerns

Adverse Effects

• Vestibular toxicity (vertigo, ataxia)VestibularUncommon
• Electrolyte disturbances (hypokalemia, hypomagnesemia)MetabolicUncommon
• Injection site pain or indurationLocalCommon
• NephrotoxicityRenalCommon
• Ototoxicity (hearing loss, tinnitus)AuditoryCommon

Drug Interactions

• Aminoglycosides (e.g., streptomycin, amikacin)High
• Neuromuscular blocking agentsModerate
• CapreomycinHigh
• Loop diuretics (e.g., furosemide)High

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative
• Patients with pre-existing renal diseaseOrgan DysfunctionRelative

Regulatory Status

• European UnionUnapprovedNot approved by the EMA; not commercially available in the European Union.
• United StatesUnapprovedNot approved by the FDA; not available commercially in the US.
• United KingdomUnapprovedNot approved by MHRA; not commercially available in the UK.

Approved in Japan for use against tuberculosis, including drug-resistant strains. Not approved by the US FDA or EMA as a standalone agent; considered an orphan/niche antibiotic in non-Japanese markets.

Evidence & Sources

• [Bactericidal activities of rifampicin, ethambutol, enviomycin and streptomycin on Mycobacterium avium-Mycobacterium intracellulare complex strains]
  Journal ArticleLowTsukamura M, Yamori S1990-01-01T00:00:00.000000Z
• Superiority of enviomycin or streptomycin over ethambutol in initial treatment of lung disease caused by Mycobacterium avium complex
  Journal ArticleLowTsukamura M, Ichiyama S, Miyachi T1989-01-01T00:00:00.000000Z
• Clinical investigation of vestibular damage by antituberculous drugs
  Journal ArticleLowNakayama M, et al.1986-01-01T00:00:00.000000Z
• [Original treatment of pulmonary tuberculosis by enviomycin (EVM)]
  Journal ArticleLowOgiwara S1987-01-01T00:00:00.000000Z
• Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors
  Journal ArticleLowde Souza AS, de Souza RF, Guzzo CR2022-01-01T00:00:00.000000Z
• Investigation of vestibular damage by antituberculous drugs
  Journal ArticleLowNakayama M, Miura H, Kamei T1991-01-01T00:00:00.000000Z

Frequently Asked Questions